

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Ryckmans Thomas :

APPLICATION NO.: 10/588,878 : Examiner: Unknown

FILING DATE: 08/09/2006 : Group Art Unit: Unknown

TITLE: Compounds Useful In Therapy :

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO/SB/08A which lists the references cited by the applicant(s).

1. US 4 481 360 A 11/02/84
2. US 7 084 164 08/01/06
3. WO 01/58880 A 08/16/01
4. EP 1 293 503 A 03/19/03
5. WO 01/87855 A 11/22/01
6. KAKEFUDA, AKIO ET AL: "Discovery of 4,5-Diphenyl-1,2,4-triazole Derivatives as a Novel Class of Selective Antagonists for the Human VIA Receptor" BIOORGANIC & MEDICINAL CHEMISTRY, 10(6), 1905-1912 CODEN: BMECEP; ISSN: 0968-0896, 2002, XP002281248
7. KAKEFUDA A ET AL: "Synthesis and pharmacological evaluation of 5-(4-bi phenyl)-3-methyl-4 phenyl-1,2,4-triazole derivatives as a novel class of selective antagonists for the human vasopressinVIA receptor" JOURNAL OF MEDICINAL AND PHARMACEUTICAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY EASTON, US, vol. 45, no. 12, 2002, pages 2589-2598, XP002237488

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). The listing of the references on the PTO/SB/08A form is not intended to represent or imply that these references are prior art to the

above-captioned application. Applicants reserve the right to challenge the status of any reference so listed or otherwise identified as prior art.

It is requested that the references listed on the attached form PTO/SB/08A be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445, including all fees required under 37 C.F.R. 1.97.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: September 20 2006

/Andrea Dorigo/
Andrea E. Dorigo. Reg. No. 47,532
Attorney for Applicant(s)

Pfizer Inc
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212) 733-1898

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	10/588,878
	Filing Date	08/08/06
	First Named Inventor	Ryckmans Thomas
	Art Unit	Unknown
	Examiner Name	Unknown
Attorney Docket Number	PC26077A	
Sheet 1 of 1		

U.S. PATENT DOCUMENTS					
EXAMINER INITIAL ^a	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
		US 4 481 360 A	11/02/84		
		US 7 084 164	08/01/06		

FOREIGN PATENT DOCUMENTS						
EXAMINER INITIAL	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		WO 01/58880 A	08/16/01			
		EP 1 293 503 A	03/19/03			
		WO 01/87855 A	11/22/01			

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹		T ²
		KAKEFUDA, AKIO ET AL: "Discovery of 4,5-Diphenyl-1,2,4- triazole Derivatives as a Novel Class of Selective Antagonists for the Human VIA Receptor" BIOORGANIC & MEDICINAL CHEMISTRY , 10(6), 1905-1912 CODEN: BMECEP; ISSN: 0968-0896, 2002, XP002281248	
		KAKEFUDA A ET AL: "Synthesis and pharmacological evaluation of 5-(4-bi phenyl)-3-methyl-4 phenyl-1,2,4- triazole derivatives as a novel class of selective antagonists for the human vasopressin/VIA receptor" JOURNAL OF MEDICINAL AND PHARMACEUTICAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY EASTON, US, vol. 45, no. 12, 2002, pages 2589-2598, XP002237488	

EXAMINER	DATE CONSIDERED
-----------------	------------------------

^a EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Application unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.